

## Online only material

Supplemental Table 1. Characteristics of HCV/HIV co-infected mothers according to whether HCV was transmitted to her infant.

Characteristic	HCV Transmission <sup>a</sup>		P
	Yes (N=16)	No (N=47)	
Age at Delivery			
Mean	31.38	31.29	0.96
Time of enrollment			
1989-2/28/94	12 (75.00)	29 (61.70)	
3/1/94- 7/31/96	1 (6.25)	9 (19.14)	
8/1/96-1999	3 (18.75)	9 (19.14)	0.45
CD4 <sup>+</sup> lymphocyte count at enrollment (cells/mm <sup>3</sup> )			
< 200	2 (15.38)	5 (11.36)	
200-350	4 (30.76)	11 (25.00)	
351-500	1 (7.69)	4 (9.09)	
> 500	6 (46.15)	24 (54.54)	0.94
Mode of delivery			
Scheduled cesarean section	2 (15.38)	4 (9.75)	
Non-scheduled cesarean section	4 (30.76)	12 (29.26)	
Vaginal birth	7 (53.84)	25 (60.97)	0.83
Duration of membrane rupture			
> 4 hours	5 (41.66)	21 (51.21)	
≤ 4 hours	7 (58.33)	20 (48.78)	0.56
Race/ ethnicity			
White	5 (31.25)	13 (27.65)	
Black	4 (25.00)	15 (31.91)	
Other	7 (43.75)	19 (40.42)	0.87
Study sites			
Boston	4 (25.00)	10 (21.27)	
New York	3 (18.75)	15 (31.91)	
Chicago	5 (31.25)	8 (17.02)	
Puerto Rico	3 (18.75)	10 (21.27)	
Houston	1 (6.25)	4 (8.51)	0.79
Antiretroviral regimen			
None	8 (50.00)	25 (53.19)	
Single-drug therapy <sup>b</sup>	5 (31.25)	14 (29.78)	
Combination therapy <sup>c</sup>	0 (0.00)	3 (6.38)	
HAART <sup>d</sup>	3 (18.75)	5 (10.63)	0.64
STD history			
Yes	7 (43.75)	29 (61.70)	
No	9 (56.25)	18 (38.29)	0.21
Income			
< \$10,000/year	11 (68.75)	35 (77.77)	
≥ \$10,000/year	5 (31.25)	10 (22.22)	0.47
Cigarette (tobacco) use			
Yes	11 (68.75)	33 (70.21)	
No	5 (31.25)	14 (29.78)	0.91
Alcohol use			
Yes	8 (50.00)	28 (59.57)	
No	8 (50.00)	19 (40.42)	0.50
Hard drug use <sup>e</sup>			
Yes	10 (62.50)	32 (68.08)	
No	6 (37.50)	15 (31.91)	0.68
Gestational age			
≥ 37 weeks	12 (75.00)	29 (61.70)	
< 37 weeks	4 (25.00)	18 (38.30)	0.34
Chorioamnionitis			
Yes	1 (6.66)	1 (2.22)	
No	14 (93.33)	44 (97.77)	0.41
Use of fetal electrodes			
Yes	1 (6.66)	1 (2.22)	
No	14 (93.33)	44 (97.77)	0.41
Infant HIV status			
Infected	5 (31.25)	8 (17.02)	
Uninfected	10 (62.50)	39 (82.97)	
Indeterminate	1 (6.25)	0 (0.00)	0.09

NOTE. Maternal factors were ascertained at final antenatal visit and refer to characteristics or behaviors during course of pregnancy. When information was missing for certain women, sum of measurements does not equal the total for all factors. P was calculated from Chi-square or F-test statistic comparing distributions among the two groups. HCV= hepatitis C virus, HIV= human immunodeficiency virus, HAART= highly active antiretroviral therapy, STD= sexually transmitted disease.

<sup>a</sup> Data are no. (%) of subjects, unless otherwise indicated.

<sup>b</sup> Single-drug therapy was defined as treatment with a single drug.

<sup>c</sup> Combination therapy was defined as either two drugs, one of which could be a protease inhibitor or a nonnucleoside reverse-transcriptase inhibitor (NNRTI), or as  $\geq$  two drugs that did not include a protease inhibitor or NNRTI, or as the combination of zidovudine, lamivudine, and abacavir.

<sup>d</sup> HAART was defined as a treatment regimen including  $\geq$  three drugs, one of which was a protease inhibitor or NNRTI.

<sup>e</sup> Cocaine, heroin or other opiates, methadone, other injecting drug use.